134 related articles for article (PubMed ID: 30345497)
1. Effect of hormonal therapy for volume reduction, lower urinary tract symptom relief and voiding symptoms in prostate cancer: leuprolide vs goserelin.
Yikilmaz TN; Ozturk E; Hizli F; Hamidi N; Basar H
Urol J; 2019 May; 16(2):157-161. PubMed ID: 30345497
[TBL] [Abstract][Full Text] [Related]
2. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
Washino S; Hirai M; Saito K; Kobayashi Y; Arai Y; Miyagawa T
Low Urin Tract Symptoms; 2018 Jan; 10(1):57-63. PubMed ID: 27943566
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
4. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
Mason M; Richaud P; Bosnyak Z; Malmberg A; Neijber A
Low Urin Tract Symptoms; 2017 May; 9(2):82-88. PubMed ID: 28394498
[TBL] [Abstract][Full Text] [Related]
5. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
[TBL] [Abstract][Full Text] [Related]
6. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.
Zhang T; Wu H; Liu S; He W; Ding K
Int Urol Nephrol; 2017 Jul; 49(7):1111-1117. PubMed ID: 28409402
[TBL] [Abstract][Full Text] [Related]
8. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
Lee JH; Kim Y; Park YW; Lee DG
J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
[TBL] [Abstract][Full Text] [Related]
9. International Prostatic Symptom Score-voiding/storage subscore ratio in association with total prostatic volume and maximum flow rate is diagnostic of bladder outlet-related lower urinary tract dysfunction in men with lower urinary tract symptoms.
Jiang YH; Lin VC; Liao CH; Kuo HC
PLoS One; 2013; 8(3):e59176. PubMed ID: 23527124
[TBL] [Abstract][Full Text] [Related]
10. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
11. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H
BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
[TBL] [Abstract][Full Text] [Related]
12. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
13. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
Anderson J; Al-Ali G; Wirth M; Gual JB; Gomez Veiga F; Colli E; van der Meulen E; Persson BE
Urol Int; 2013; 90(3):321-8. PubMed ID: 23258223
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
15. Lower urinary tract symptoms in patients with advanced prostate cancer: What are the outcomes of androgen deprivation therapy?
Akpayak IC; Shuaibu SI; Ofoha CG; Dakum NK; Ramyil VM; Onowa VE; Agbo CA; Nabasu LE; Galam ZZ
Niger Postgrad Med J; 2020; 27(1):49-53. PubMed ID: 32003362
[TBL] [Abstract][Full Text] [Related]
16. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.
Dias Silva É; Ferreira U; Matheus W; Faria EF; Silva GD; Saito M; de Souza AA; Laranjo A; Clark O; Magna LA; Castilho LN; Reis LO
Int Urol Nephrol; 2012 Aug; 44(4):1039-44. PubMed ID: 22315155
[TBL] [Abstract][Full Text] [Related]
17. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
18. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
Haliloglu A; Baltaci S; Yaman O
J Urol; 2007 Jan; 177(1):128-30. PubMed ID: 17162022
[TBL] [Abstract][Full Text] [Related]
19. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
Cho MC; Yoo S; Park J; Cho SY; Son H; Oh SJ; Paick JS
BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
[TBL] [Abstract][Full Text] [Related]
20. Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer.
Tanaka N; Fujimoto K; Hirao Y; Shimizu K; Tsujimoto S; Samma S
Arch Androl; 2007; 53(2):87-90. PubMed ID: 17453688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
